Background. Transcatheter aortic valve implantation (TAVI) has been proposed as a therapeutic option for high-risk or inoperable patients with severe symptomatic aortic valve stenosis. The aim of this multicenter study was to assess early and medium term outcomes of transapical aortic valve implantation (TA-TAVI). Methods. From April 2008 through June 2012, a total of 774 patients were enrolled in the Italian Registry of Trans-Apical Aortic Valve Implantation (I-TA). Twenty-one centers were included in the I-TA registry. Outcomes were also analyzed according to the impact of the learning curve (first 50% cases versus second 50% cases of each center) and of the procedural volume (high-volume versus low-volume centers). Results. Mean age was 81.0 +/- 6.7 years, mean logistic European System for Cardiac Operative Risk Evaluation (EuroSCORE) I, EuroSCORE II, and The Society of Thoracic Surgeons risk score were 25.6% +/- 16.3%, 9.4% +/- 11.0%, and 10.6% +/- 8.5%, respectively. Median follow-up was 12 months (range, 1 to 44). Thirty-day mortality was 9.9% (77 patients). Overall 1-, 2-, and 3-year survival was 81.7% +/- 1.5%, 76.1% +/- 1.9%, and 67.6% +/- 3.2%, respectively. Thirty-day mortality of the first 50% patients of each center was higher when compared with the second half (p = 0.04) but 3-year survival was not different (p = 0.64). Conversely, 30-day mortality at low-volume centers versus high-volume centers was similar (p = 0.22). At discharge, peak and mean transprosthetic gradients were 21.0 +/- 10.3 mm Hg and 10.2 +/- 4.1 mm Hg, respectively. These values remained stable 12 and 24 months after surgery. Conclusions. Transapical TAVI provides good results in terms of early and midterm clinical and hemodynamic outcomes. Thus it appears to be a safe and effective alternative treatment for patients who are inoperable or have high surgical risk. (C) 2013 by The Society of Thoracic Surgeons

Medium Term Outcomes of Transapical Aortic Valve Implantation: Results From the Italian Registry of Trans-Apical Aortic Valve Implantation / D'Onofrio A; Salizzoni S; Agrifoglio M; Cota L; Luzi G; Tartara PM; Cresce GD; Aiello M; Savini C; Cassese M; Cerillo A; Punta G; Cioni M; Gabbieri D; Zanchettin C; Agostinelli A; Mazzaro E; Di Gregorio O; Gatti G; Faggian G; Filippini C; Rinaldi M; Gerosa G. - In: ANNALS OF THORACIC SURGERY. - ISSN 0003-4975. - 96:(2013), pp. 830-836. [10.1016/j.athoracsur.2013.04.094]

Medium Term Outcomes of Transapical Aortic Valve Implantation: Results From the Italian Registry of Trans-Apical Aortic Valve Implantation

Cerillo A;
2013

Abstract

Background. Transcatheter aortic valve implantation (TAVI) has been proposed as a therapeutic option for high-risk or inoperable patients with severe symptomatic aortic valve stenosis. The aim of this multicenter study was to assess early and medium term outcomes of transapical aortic valve implantation (TA-TAVI). Methods. From April 2008 through June 2012, a total of 774 patients were enrolled in the Italian Registry of Trans-Apical Aortic Valve Implantation (I-TA). Twenty-one centers were included in the I-TA registry. Outcomes were also analyzed according to the impact of the learning curve (first 50% cases versus second 50% cases of each center) and of the procedural volume (high-volume versus low-volume centers). Results. Mean age was 81.0 +/- 6.7 years, mean logistic European System for Cardiac Operative Risk Evaluation (EuroSCORE) I, EuroSCORE II, and The Society of Thoracic Surgeons risk score were 25.6% +/- 16.3%, 9.4% +/- 11.0%, and 10.6% +/- 8.5%, respectively. Median follow-up was 12 months (range, 1 to 44). Thirty-day mortality was 9.9% (77 patients). Overall 1-, 2-, and 3-year survival was 81.7% +/- 1.5%, 76.1% +/- 1.9%, and 67.6% +/- 3.2%, respectively. Thirty-day mortality of the first 50% patients of each center was higher when compared with the second half (p = 0.04) but 3-year survival was not different (p = 0.64). Conversely, 30-day mortality at low-volume centers versus high-volume centers was similar (p = 0.22). At discharge, peak and mean transprosthetic gradients were 21.0 +/- 10.3 mm Hg and 10.2 +/- 4.1 mm Hg, respectively. These values remained stable 12 and 24 months after surgery. Conclusions. Transapical TAVI provides good results in terms of early and midterm clinical and hemodynamic outcomes. Thus it appears to be a safe and effective alternative treatment for patients who are inoperable or have high surgical risk. (C) 2013 by The Society of Thoracic Surgeons
2013
96
830
836
D'Onofrio A; Salizzoni S; Agrifoglio M; Cota L; Luzi G; Tartara PM; Cresce GD; Aiello M; Savini C; Cassese M; Cerillo A; Punta G; Cioni M; Gabbieri D;...espandi
File in questo prodotto:
File Dimensione Formato  
43. D'onofrio et al. Ann thorac surg 2013.pdfpdf.pdf

Accesso chiuso

Licenza: Tutti i diritti riservati
Dimensione 472.56 kB
Formato Adobe PDF
472.56 kB Adobe PDF   Richiedi una copia

I documenti in FLORE sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificatore per citare o creare un link a questa risorsa: https://hdl.handle.net/2158/1404178
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 43
  • ???jsp.display-item.citation.isi??? 44
social impact